

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Soumya P. Sahoo, et al.		
Serial No.:	TO BE ASSIGNED	Case No.: 20768	Art Unit: To Be Assigned
Filed:	October 29, 2001		
For:	BENZOPYRANCARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS		Examiner: To Be Assigned

Honorable Assistant Commissioner for Patents  
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Please amend the specification by adding the following sentence after the title and before the Field of the Invention section:

-- CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority from US Provisional Application No. 60/244,698, filed on October 31, 2000, which is incorporated by reference into this application in its entirety.--

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT October 29, 2001

EXPRESS MAIL NO. EL523910388US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE ADDRESSEE" BEFORE 5 P.M. ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.

MAILED BY *Rinda Zhrer*

DATE October 29, 2001

In the Claims

Please also amend Claims 14, 27, 31, 32, and 35 so that they read as shown below:

14. (Amended) A compound having formula I as recited in Claim 1, wherein R<sup>3</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, and R<sup>10</sup> are H; R<sup>2</sup> is Cl or F; and R<sup>1</sup> is C<sub>1-4</sub>alkyl, Cl or F, where C<sub>1-4</sub>alkyl is linear or branched and is optionally substituted with 1-5 F.

27. (Amended) A compound having formula I as recited in Claim 1, wherein R<sup>3</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, and R<sup>10</sup> are H; R<sup>1</sup> is C<sub>1-4</sub>alkyl, Cl or F; and R<sup>2</sup> is Cl or F.

31. (Amended) A compound as recited in Claim 1, wherein the stereochemistry at the 2-position of the benzopyranyl ring is R.

32. (Amended) A compound as recited in Claim 1, wherein the stereochemistry at the 2-position of the benzopyranyl ring is S.

35. (Amended) A pharmaceutical composition comprising a compound as identified in Claim 1 and a pharmaceutically acceptable carrier.

Date: October 29, 2001

Attachment Showing Amendments to Claims

14. (Amended) A compound having formula I as recited in Claim 1, [any one of Claims 1-13,] wherein R<sup>3</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, and R<sup>10</sup> are H; R<sup>2</sup> is Cl or F; and R<sup>1</sup> is C<sub>1-4</sub>alkyl, Cl or F, where C<sub>1-4</sub>alkyl is linear or branched and is optionally substituted with 1-5 F.

27. (Amended) A compound having formula I as recited in Claim 1, [any one of Claims 1-26,] wherein R<sup>3</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, and R<sup>10</sup> are H; R<sup>1</sup> is C<sub>1-4</sub>alkyl, Cl or F; and R<sup>2</sup> is Cl or F.

31. (Amended) A compound as recited in Claim 1, [any one of Claims 1-30,] wherein the stereochemistry at the 2-position of the benzopyranyl ring is R.

32. (Amended) A compound as recited in Claim 1, [any one of Claims 1-30,] wherein the stereochemistry at the 2-position of the benzopyranyl ring is S.

35. (Amended) A pharmaceutical composition comprising a compound as identified in Claim 1 [any of Claims 1-34] and a pharmaceutically acceptable carrier.